Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H19F2N3O3 |
| Molecular Weight | 387.38 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C(=O)C1=CC(O[C@H]2CCOC3=CC(F)=CC(F)=C23)=C4NC(C)=NC4=C1
InChI
InChIKey=CLIQCDHNPDMGSL-HNNXBMFYSA-N
InChI=1S/C20H19F2N3O3/c1-10-23-14-6-11(20(26)25(2)3)7-17(19(14)24-10)28-15-4-5-27-16-9-12(21)8-13(22)18(15)16/h6-9,15H,4-5H2,1-3H3,(H,23,24)/t15-/m0/s1
| Molecular Formula | C20H19F2N3O3 |
| Molecular Weight | 387.38 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Tegoprazan is an oral, selective, reversible inhibitor of gastric H+/K+-ATPase that has a fast onset of action and can control gastric pH for a prolonged period. It was developed for the treatment of acid-related gastrointestinal diseases such as gastroesophageal reflux disease (GERD) and peptic ulcers. Tegoprazan has received a license from the Ministry of Food and Drug Safety in Korea for the treatment of gastroesophageal reflux disease and erosive oesophagitis. In addition, the drug is involved in phase III clinical trial to evaluate the triple therapy (tegoprazan, amoxicillin, and clarithromycin) in H. Pylori positive patients. This trial is on the stage of recruiting the patients.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. | 2019 Apr |
|
| Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid-Related Disease. | 2019 Jun |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:44:32 GMT 2023
by
admin
on
Fri Dec 15 19:44:32 GMT 2023
|
| Record UNII |
W017G7IF4S
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29723
Created by
admin on Fri Dec 15 19:44:32 GMT 2023 , Edited by admin on Fri Dec 15 19:44:32 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
300000020956
Created by
admin on Fri Dec 15 19:44:32 GMT 2023 , Edited by admin on Fri Dec 15 19:44:32 GMT 2023
|
PRIMARY | |||
|
10169
Created by
admin on Fri Dec 15 19:44:32 GMT 2023 , Edited by admin on Fri Dec 15 19:44:32 GMT 2023
|
PRIMARY | |||
|
23582846
Created by
admin on Fri Dec 15 19:44:32 GMT 2023 , Edited by admin on Fri Dec 15 19:44:32 GMT 2023
|
PRIMARY | |||
|
942195-55-3
Created by
admin on Fri Dec 15 19:44:32 GMT 2023 , Edited by admin on Fri Dec 15 19:44:32 GMT 2023
|
PRIMARY | |||
|
C152542
Created by
admin on Fri Dec 15 19:44:32 GMT 2023 , Edited by admin on Fri Dec 15 19:44:32 GMT 2023
|
PRIMARY | |||
|
DB16690
Created by
admin on Fri Dec 15 19:44:32 GMT 2023 , Edited by admin on Fri Dec 15 19:44:32 GMT 2023
|
PRIMARY | |||
|
W017G7IF4S
Created by
admin on Fri Dec 15 19:44:32 GMT 2023 , Edited by admin on Fri Dec 15 19:44:32 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
